Email ID
Password
Scrip   
MannKind's inhaled insulin product faces US delay
15 January 2010
Katie McQue

The US FDA has told MannKind that it will miss the January 16th user fee date for the NDA of its inhaled rapid-acting insulin product Afrezza (formerly Afresa). The drug is awaiting a decision for the treatment of adults with types 1 and 2 diabetes for the control of hyperglycaemia.

According...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36